• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HIV阴性患者耶氏肺孢子菌肺炎的易感因素、临床特征及预后

Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients.

作者信息

Kofteridis Diamantis P, Valachis Antonis, Velegraki Maria, Antoniou Maria, Christofaki Maria, Vrentzos George E, Andrianaki Angeliki M, Samonis George

机构信息

Department of Internal Medicine, University Hospital of Heraklion, Crete, Greece.

Department of Oncology, Mälarsjukhuset Eskilstuna, Sweden.

出版信息

J Infect Chemother. 2014 Jul;20(7):412-6. doi: 10.1016/j.jiac.2014.03.003. Epub 2014 Apr 22.

DOI:10.1016/j.jiac.2014.03.003
PMID:24767467
Abstract

Pneumocystis jirovecii (former carinii) pneumonia, is a life-threatening opportunistic infection occurring in immunocompromised hosts. The aim of this study was to investigate the predisposing factors, clinical features and outcome of Pneumocystis pneumonia (PCP) in HIV-negative patients. The medical records of 62 adult patients with PCP, hospitalized at the University Hospital of Heraklion, Crete, Greece during a 10-year period (2004-2013) were retrospectively reviewed. All patients were immunosuppressed prior to the development of PCP. Thirty one patients (50%) suffered malignant hematological disease, 16 (26%) solid tumor and 15 (24%) had chronic inflammatory disease. Only 17 (27%) had received long-term systemic corticosteroids. All had symptoms of pneumonia upon admission, while 12 (19%) were suffering respiratory failure. Twenty one (34%) had received trimethoprim/sulfamethoxazole (TMP-SMX) prophylaxis before the PCP onset. Eight patients (13%) were admitted to the ICU. Mortality attributable to PCP reached 29%. Mortality attributable to PCP was higher in patients with solid tumors. TMP-SMX prophylaxis failed in a significant portion of the present cohort. Hence, PCP should be included in the differential diagnosis in immunocompromised patients with symptoms from the respiratory tract even if TMP-SMX has been given as prophylaxis.

摘要

耶氏肺孢子菌(原称卡氏肺孢子菌)肺炎是一种发生于免疫功能低下宿主的危及生命的机会性感染。本研究旨在调查HIV阴性患者肺孢子菌肺炎(PCP)的易感因素、临床特征及预后。对希腊克里特岛伊拉克利翁大学医院在10年期间(2004 - 2013年)住院的62例成年PCP患者的病历进行了回顾性分析。所有患者在发生PCP之前均处于免疫抑制状态。31例患者(50%)患有恶性血液病,16例(26%)患有实体瘤,15例(24%)患有慢性炎症性疾病。只有17例(27%)接受过长期全身性皮质类固醇治疗。所有患者入院时均有肺炎症状,其中12例(19%)出现呼吸衰竭。21例(34%)在PCP发病前接受过甲氧苄啶/磺胺甲恶唑(TMP - SMX)预防治疗。8例患者(13%)入住重症监护病房。PCP导致的死亡率达29%。实体瘤患者中PCP导致的死亡率更高。在本队列的很大一部分患者中,TMP - SMX预防治疗失败。因此,即使已给予TMP - SMX进行预防,对于有呼吸道症状的免疫功能低下患者,也应将PCP纳入鉴别诊断。

相似文献

1
Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients.HIV阴性患者耶氏肺孢子菌肺炎的易感因素、临床特征及预后
J Infect Chemother. 2014 Jul;20(7):412-6. doi: 10.1016/j.jiac.2014.03.003. Epub 2014 Apr 22.
2
Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients.HIV阴性患者耶氏肺孢子菌肺炎的易感因素、临床特征及转归
Kansenshogaku Zasshi. 2014 Nov;88(6 Suppl 11):21-5.
3
Efficacies of atovaquone, pentamidine, and trimethoprim/sulfamethoxazole for the prevention of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.阿托伐醌、喷他脒和甲氧苄啶/磺胺甲恶唑对结缔组织病患者预防耶氏肺孢子菌肺炎的疗效。
J Infect Chemother. 2019 May;25(5):351-354. doi: 10.1016/j.jiac.2019.01.005. Epub 2019 Jan 31.
4
Diagnosis and treatment of Pneumocystis jirovecii pneumonia in HIV-infected or non-HIV-infected patients-difficulties in diagnosis and adverse effects of trimethoprim-sulfamethoxazole.HIV 感染者和非 HIV 感染者中肺孢子菌肺炎的诊断和治疗——诊断困难和复方磺胺甲噁唑的不良反应。
J Infect Chemother. 2019 Nov;25(11):920-924. doi: 10.1016/j.jiac.2019.06.007. Epub 2019 Jul 9.
5
Underlying renal insufficiency: the pivotal risk factor for Pneumocystis jirovecii pneumonia in immunosuppressed patients with non-transplant glomerular disease.潜在肾功能不全:非移植性肾小球疾病免疫抑制患者发生耶氏肺孢子菌肺炎的关键危险因素。
Int Urol Nephrol. 2016 Nov;48(11):1863-1871. doi: 10.1007/s11255-016-1324-x. Epub 2016 Jun 28.
6
Tolerability of low-dose sulfamethoxazole/trimethoprim for Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients.低剂量磺胺甲恶唑/甲氧苄啶用于肾移植受者预防耶氏肺孢子菌肺炎的耐受性
Prog Transplant. 2015 Sep;25(3):210-6. doi: 10.7182/pit2015153.
7
Epidemiology and risk factors associated with Pneumocystis jirovecii pneumonia in kidney transplant recipients after 6-month trimethoprim-sulfamethoxazole prophylaxis: A case-control study.接受6个月甲氧苄啶-磺胺甲恶唑预防治疗的肾移植受者中与耶氏肺孢子菌肺炎相关的流行病学及危险因素:一项病例对照研究
Transpl Infect Dis. 2020 Apr;22(2):e13245. doi: 10.1111/tid.13245. Epub 2020 Jan 24.
8
Pneumocystis jirovecii pneumonia in kidney transplantation.肾移植受者中的耶氏肺孢子菌肺炎
Transpl Infect Dis. 2011 Dec;13(6):551-8. doi: 10.1111/j.1399-3062.2011.00691.x. Epub 2011 Oct 31.
9
Pneumocystis jirovecii pneumonia in patients with and without human immunodeficiency virus infection.伴有和不伴有人类免疫缺陷病毒感染患者的耶氏肺孢子菌肺炎
J Microbiol Immunol Infect. 2008 Dec;41(6):478-82.
10
Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients.对于感染HIV的患者,使用每日10毫克/千克甲氧苄啶-50毫克/千克磺胺甲恶唑治疗耶氏肺孢子菌肺炎效果良好。
Scand J Infect Dis. 2009;41(11-12):862-8. doi: 10.3109/00365540903214256.

引用本文的文献

1
Non-linear association between neutrophil-to-lymphocyte ratio and 90-day mortality in patients with pneumonia receiving glucocorticoids alone or in combination with other immunosuppressants: A retrospective cohort study.单独使用糖皮质激素或联合其他免疫抑制剂治疗的肺炎患者中,中性粒细胞与淋巴细胞比值与90天死亡率之间的非线性关联:一项回顾性队列研究。
PLoS One. 2025 Aug 18;20(8):e0329616. doi: 10.1371/journal.pone.0329616. eCollection 2025.
2
An overview of the laboratory diagnosis of pneumonia.肺炎的实验室诊断概述。
J Clin Microbiol. 2025 Mar 12;63(3):e0036124. doi: 10.1128/jcm.00361-24. Epub 2025 Feb 3.
3
Atypical presentation of PJP: hypercalcemia and kidney injury in an allogeneic stem cell transplant recipient.
PJP 的非典型表现:异基因干细胞移植受者的高钙血症和肾损伤。
BMC Infect Dis. 2024 Oct 24;24(1):1201. doi: 10.1186/s12879-024-10074-z.
4
Outcome of Pneumocystis Jirovecii pneumonia (PcP) in post-CAR-T patients with hematological malignancies.血液恶性肿瘤 CAR-T 治疗后患者肺孢子菌肺炎(PcP)的结局。
BMC Infect Dis. 2024 Oct 13;24(1):1147. doi: 10.1186/s12879-024-09893-x.
5
Diagnostic values of BALF metagenomic next-generation sequencing, BALF real-time PCR and serum BDG for pneumonia in HIV-infected patients.支气管肺泡灌洗液宏基因组下一代测序、支气管肺泡灌洗液实时荧光定量聚合酶链反应及血清β-葡聚糖检测对HIV感染患者肺炎的诊断价值
Front Microbiol. 2024 Sep 20;15:1421660. doi: 10.3389/fmicb.2024.1421660. eCollection 2024.
6
Protocol for the systematic review of the Pneumocystis jirovecii-associated pneumonia in non-HIV immunocompromised patients.非 HIV 免疫功能低下患者中肺孢子菌肺炎的系统评价方案。
PLoS One. 2024 May 9;19(5):e0302055. doi: 10.1371/journal.pone.0302055. eCollection 2024.
7
Pneumocystis jirovecii pneumonia mortality risk associated with preceding long-term steroid use for the underlying disease: A multicenter, retrospective cohort study.特发性肺孢子菌肺炎死亡率与潜在疾病先前长期使用类固醇相关:一项多中心回顾性队列研究。
PLoS One. 2024 Feb 8;19(2):e0292507. doi: 10.1371/journal.pone.0292507. eCollection 2024.
8
Pneumonia after Heart Transplantation: Two Case Reports and a Review of the Literature.心脏移植术后肺炎:两例报告及文献综述
Pathogens. 2023 Oct 21;12(10):1265. doi: 10.3390/pathogens12101265.
9
Incidence of Pneumocystis Jiroveci Pneumonia in Patients With ANCA-Associated Vasculitis Initiating Therapy With Rituximab or Cyclophosphamide.利妥昔单抗或环磷酰胺治疗初治抗中性粒细胞胞浆抗体相关性血管炎患者中肺孢子菌肺炎的发生率。
Arthritis Care Res (Hoboken). 2024 Feb;76(2):288-294. doi: 10.1002/acr.25222. Epub 2023 Oct 28.
10
Trends in the Epidemiology of Pneumonia in Immunocompromised Patients without HIV Infection.无HIV感染的免疫功能低下患者肺炎的流行病学趋势
J Fungi (Basel). 2023 Jul 31;9(8):812. doi: 10.3390/jof9080812.